Article Details

Roche's gantenerumab failure boosts prospects for Eisai and Biogen's lecanemab

Retrieved on: 2022-11-17 17:02:07

Tags for this article:

Click the tags to see associated articles and topics

Roche's gantenerumab failure boosts prospects for Eisai and Biogen's lecanemab. View article details on hiswai:

Excerpt

Credit: Taljat David / Shutterstock. On 14 November, Roche announced that its anti-amyloid beta (Aβ) monoclonal antibody ( ...

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up